PML in 2026: beyond recognition and towards treatment
Practical Neurology · 2026-12 · 26 (6) · 526-528
DOI: 10.1136/pn-2026-005285 ↗Kurz gefasst
Editorial in der Zeitschrift Practical Neurology, online erschienen am 10.07.2026. Verfasst von Shaza Almweisheer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
checkpoint inhibitor (ICI) therapy due to progressive PML. A 50- year-old man with grade 2 follicular lymphoma had taken chemotherapy for 1 year and had received rituximab maintenance treatment. He presented with subacute encephalopathy, aphasia and partial Gerstmann syndrome. PML was diagnosed based on imaging findings (G) and CSF JCV PCR testing. Despite stopping rituximab, he had clinical and radiological progression over 6 weeks (H). He received three doses of nivolumab on an experimental basis, resulting in disease stabilisation at 1-year follow-up (I).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
- King Fahad Medical City, National Neuroscience Institute, Riyadh, Saudi Arabia.
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Ronak.Kapadia@ahs.ca.
Zitieren
APA
Almweisheer, S., & Kapadia, R. K. (2026). PML in 2026: beyond recognition and towards treatment. Practical Neurology, 26(6), 526-528. https://doi.org/10.1136/pn-2026-005285
Vancouver
Almweisheer S, Kapadia RK. PML in 2026: beyond recognition and towards treatment. Practical Neurology. 2026;26(6):526-528. doi:10.1136/pn-2026-005285
BibTeX
@article{Almweisheer2026,
author = {Almweisheer, Shaza and Kapadia, Ronak K},
title = {PML in 2026: beyond recognition and towards treatment},
journal = {Practical Neurology},
year = {2026},
volume = {26},
number = {6},
pages = {526--528},
doi = {10.1136/pn-2026-005285}
}
EUVIMED